Warfarin

David Green, Gordon Caldwell, Anthony D. Toft, Paul A. Lotke, David G. Pfister, Malcolm L. Ecker, Philip W. Yule, Stanford Wessler, Sanford N. Gitel

Research output: Contribution to journalLetter

7 Scopus citations

Abstract

To the Editor: With regard to the excellent review of warfarin by Wessler and Gitel (Sept. 6 issue),1 the importance of protein C in preventing thrombosis in patients treated with warfarin has recently been emphasized by two reports of the development of skin and soft-tissue necrosis in warfarin-treated patients with a hereditary protein C deficiency.2,3 A review of 17 previously reported cases of warfarin necrosis revealed that in all but 2 the onset of thrombosis coincided with prothrombin times that exceeded the therapeutic range, and it occurred within the first five days of treatment, suggesting extreme sensitivity to the hypoprothrombinemic.

Original languageEnglish (US)
Pages (from-to)1578-1580
Number of pages3
JournalNew England Journal of Medicine
Volume311
Issue number24
DOIs
Publication statusPublished - Dec 13 1984

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Green, D., Caldwell, G., Toft, A. D., Lotke, P. A., Pfister, D. G., Ecker, M. L., ... Gitel, S. N. (1984). Warfarin. New England Journal of Medicine, 311(24), 1578-1580. https://doi.org/10.1056/NEJM198412133112418